RNS Number : 0387D
BioPharma Credit PLC
24 June 2021
BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF GM AND AGM
General Meeting
The Company is pleased to announce that, at the General Meeting held today, both resolutions were put to the meeting and passed on a show of hands.
The proxy votes received in relation to this resolution was as follows:
|
Resolutions
|
Votes
For
|
%
|
Votes Against
|
%
|
Votes at Chairman's Discretion
|
Votes Withheld
|
|
1: To appoint PricewaterhouseCoopers LLP as auditor to the Company
|
603,573,041
|
98.37
|
10,013,980
|
1.63
|
0
|
0
|
|
2: To authorise the Directors to determine the remuneration of
PricewaterhouseCoopers LLP as
the auditor
|
613,573,041
|
99.99
|
13,980
|
0.01
|
0
|
0
|
Annual General Meeting
The Company is pleased to announce that, at the Annual General Meeting that was adjourned on 17 June 2021 and reconvened today, Resolution 1 was put to the meeting and passed on a show of hands.
The proxy votes received in relation to this resolution was as follows:
|
Resolutions
|
Votes
For
|
%
|
Votes Against
|
%
|
Votes at Chairman's Discretion
|
Votes Withheld
|
|
1: To receive and accept the annual report and financial statements
|
644,324,577
|
100
|
0
|
0
|
0
|
0
|
24 June 2021
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
+44 (0)20 7466 5000 / [email protected]
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
RAGFIMTTMTBTBRB